Demand for VScan diagnostic test kits increases

NewsGuard 100/100 Score

Medical Services International Inc has announced that as the mosquito season begins in different parts of the world; demand for the VScan diagnostic test kits that detect mosquito borne diseases is increasing. In particular, the demand is for VScan test kits that detect Malaria, Dengue Fever and West Nile.

Based on initial discussions with distributors, it appears that the Company will supply in excess of 800,000 VScan test kits that detect mosquito borne diseases during this mosquito season. The Company believes that the VScan test kits will perform so well this season that it will result in significant future sales exceeding several million kits per year. All of these kits have a gross value in excess of $2.25 US per kit.

The VScan rapid test kit is a single use, disposable, accurate, cost effective, easy to use, test for the screening of HIV 1&2, hepatitis B&C, Tuberculosis (TB), Dengue Fever, Malaria, West Nile, Syphilis and Prostate Cancer. The kits cannot be sold in Canada.

Medical Services International Inc trades in the United States on the NQB Pinksheets under the symbol "MSITF". For further information, please contact Robert Talbot at (780) 430 6363 or http://www.medicalservicesintl.com/ or http://www.minerva-biotech.com.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Pre-vaccine COVID-19: US study reveals hospitalization rate of 5.7% and fatality rate of 1.7%